These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 20072841)
41. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823 [TBL] [Abstract][Full Text] [Related]
42. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. Hugle M; Belz K; Fulda S Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389 [TBL] [Abstract][Full Text] [Related]
43. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. Choi M; Kim W; Cheon MG; Lee CW; Kim JE Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551 [TBL] [Abstract][Full Text] [Related]
44. The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Vose JM; Friedberg JW; Waller EK; Cheson BD; Juvvigunta V; Fritsch H; Petit C; Munzert G; Younes A Leuk Lymphoma; 2013 Apr; 54(4):708-13. PubMed ID: 22978685 [TBL] [Abstract][Full Text] [Related]
45. Non-mitotic functions of polo-like kinases in cancer cells. Raab CA; Raab M; Becker S; Strebhardt K Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265 [TBL] [Abstract][Full Text] [Related]
46. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53. Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681 [TBL] [Abstract][Full Text] [Related]
47. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells. Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075 [TBL] [Abstract][Full Text] [Related]
48. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Francescangeli F; Patrizii M; Signore M; Federici G; Di Franco S; Pagliuca A; Baiocchi M; Biffoni M; Ricci Vitiani L; Todaro M; De Maria R; Zeuner A Stem Cells; 2012 Sep; 30(9):1819-30. PubMed ID: 22753241 [TBL] [Abstract][Full Text] [Related]
49. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Renner AG; Dos Santos C; Recher C; Bailly C; Créancier L; Kruczynski A; Payrastre B; Manenti S Blood; 2009 Jul; 114(3):659-62. PubMed ID: 19458358 [TBL] [Abstract][Full Text] [Related]
50. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity. Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535 [TBL] [Abstract][Full Text] [Related]
52. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Wang Y; Wu L; Yao Y; Lu G; Xu L; Zhou J Cancer Lett; 2018 Nov; 436():1-9. PubMed ID: 30118839 [TBL] [Abstract][Full Text] [Related]
53. PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia. Oliveira JC; Pezuk JA; Brassesco MS; Morales AG; Queiroz RG; Scrideli CA; Tone LG Pediatr Blood Cancer; 2014 Jul; 61(7):1227-31. PubMed ID: 24519995 [TBL] [Abstract][Full Text] [Related]
55. Polo-like kinase and its inhibitors: Ready for the match to start? Palmisiano ND; Kasner MT Am J Hematol; 2015 Nov; 90(11):1071-6. PubMed ID: 26294255 [TBL] [Abstract][Full Text] [Related]
56. Polo-like kinase inhibitors in hematologic malignancies. Talati C; Griffiths EA; Wetzler M; Wang ES Crit Rev Oncol Hematol; 2016 Feb; 98():200-10. PubMed ID: 26597019 [TBL] [Abstract][Full Text] [Related]
57. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1. Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161 [TBL] [Abstract][Full Text] [Related]
58. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Morales AG; Brassesco MS; Pezuk JA; Oliveira JC; Montaldi AP; Sakamoto-Hojo ET; Scrideli CA; Tone LG Anticancer Drugs; 2011 Nov; 22(10):995-1001. PubMed ID: 21822121 [TBL] [Abstract][Full Text] [Related]
60. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. Wissing MD; Mendonca J; Kortenhorst MS; Kaelber NS; Gonzalez M; Kim E; Hammers H; van Diest PJ; Carducci MA; Kachhap SK FASEB J; 2013 Oct; 27(10):4279-93. PubMed ID: 23884428 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]